Prado, José C Ruilope Urioste, Luis Miguel Segura de la Morena, Julián
Utilidad de la espironolactona en el manejo farmacológico de la hipertensión arterial resistente. Comentarios sobre el estudio Pathway-2. [revisión] - Hipertensión y riesgo vascular, 2016 - 33(4):150-4.
Formato Vancouver:
Prado JC, Ruilope LM, Segura J. Utilidad de la espironolactona en el manejo farmacológico de la hipertensión arterial resistente. Comentarios sobre el estudio Pathway-2. Hipertens Riesgo Vasc. 2016 Oct-Dec;33(4):150-4.
PMID: 27363610
Contiene 44 referencias
Pathway-2 is the first randomised, double-blind and crossover trial that compares spironolactone as a fourth drug with alfa-blocker, beta-blocker and placebo. This study shows that spironolactone is the drug with more possibilities of success for the management of patients with difficult-to-treat hypertension in patients with a combination of three drugs and poor control. The results validate the widespread treatment with mineralocorticoid receptor antagonists in resistant hypertension.
Utilidad de la espironolactona en el manejo farmacológico de la hipertensión arterial resistente. Comentarios sobre el estudio Pathway-2. [revisión] - Hipertensión y riesgo vascular, 2016 - 33(4):150-4.
Formato Vancouver:
Prado JC, Ruilope LM, Segura J. Utilidad de la espironolactona en el manejo farmacológico de la hipertensión arterial resistente. Comentarios sobre el estudio Pathway-2. Hipertens Riesgo Vasc. 2016 Oct-Dec;33(4):150-4.
PMID: 27363610
Contiene 44 referencias
Pathway-2 is the first randomised, double-blind and crossover trial that compares spironolactone as a fourth drug with alfa-blocker, beta-blocker and placebo. This study shows that spironolactone is the drug with more possibilities of success for the management of patients with difficult-to-treat hypertension in patients with a combination of three drugs and poor control. The results validate the widespread treatment with mineralocorticoid receptor antagonists in resistant hypertension.
